A total of 740 patients with COVID-19 also experienced myocarditis, compared to 55 patients who had flu and 65 with RSV. The ...

Background: Prior studies of cardiac rhythm management devices (pacemakers [PM] and implantable cardioverter defibrillators [ICD]) utilization in the United States have been limited to the ...

Heart failure and arrhythmias together pose a critical healthcare issue with high risks of morbidity and mortality globally. Emerging evidence underscores ...

Absent or delayed therapy may be caused by programmed values (including human error), ICD system performance, or a combination of the two. The most common causes are ICD inactivation, VT slower ...

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy TA117 24 January 2007 24 January 2007 Methadone and buprenorphine ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

QuANTUM-Wild is a randomized, double-blind, placebo-controlled global phase 3 trial evaluating the efficacy and safety of VANFLYTA in combination with standard intensive induction and ...